** Amgen AMGN.O said on Thursday its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing
** Median PT of brokerages covering the stock is $315.46 - data compiled by LSEG
FOCUS REMAINS ON MARITIDE
** Mizuho ("Neutral", PT: $235) believes many questions remain unanswered on experimental weight-loss drug MariTide, viewed by many investors as a potential blockbuster
** J.P.Morgan ("Neutral", PT: $283.78) expects shares to "remain range bound pending longer-term obesity updates for MariTide"
** RBC Capital Markets ("Outperform", PT: $320) believes greater visibility into critical inflection points for Horizon-derived products in the rare disease space, like thyroid eye disease drug Tepezza, gout treatment Krystexxa, and immune disorder drug Uplizna is necessary to bolster investor confidence
** Piper Sandler ("Overweight", PT: $329) says Amgen's strategy of launching new biosimilars will help in "cushioning the impact" by offsetting the revenue loss from products losing their patent protection
** Citi ("Neutral", PT: $300) says they are positive of AMGN's rare product portfolio from the Horizon acquisition
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。